Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7LKE

X-ray crystal structure of the SARS-CoV-2 main protease in space group C2

Summary for 7LKE
Entry DOI10.2210/pdb7lke/pdb
Related7LBN
Descriptor3C-like proteinase (1 entity in total)
Functional Keywordsprotease, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV,SARS-CoV-2)
Total number of polymer chains1
Total formula weight33825.55
Authors
Narwal, M.,Murakami, K.S. (deposition date: 2021-02-02, release date: 2021-04-14, Last modification date: 2023-10-18)
Primary citationNarayanan, A.,Narwal, M.,Majowicz, S.A.,Varricchio, C.,Toner, S.A.,Ballatore, C.,Brancale, A.,Murakami, K.S.,Jose, J.
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
Commun Biol, 5:169-169, 2022
Cited by
PubMed Abstract: SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug development. In this study, we present an antiviral screening strategy involving a novel in-cell protease assay, antiviral and biochemical activity assessments, as well as structural determinations for rapid identification of protease inhibitors with low cytotoxicity. We identified eight compounds with anti-SARS-CoV-2 activity from a library of 64 repurposed drugs and modeled at protease active sites by in silico docking. We demonstrate that Sitagliptin and Daclatasvir inhibit PLpro, and MG-101, Lycorine HCl, and Nelfinavir mesylate inhibit Mpro of SARS-CoV-2. The X-ray crystal structure of Mpro in complex with MG-101 shows a covalent bond formation between the inhibitor and the active site Cys145 residue indicating its mechanism of inhibition is by blocking the substrate binding at the active site. Thus, we provide methods for rapid and effective screening and development of inhibitors for blocking virus polyprotein processing as SARS-CoV-2 antivirals. Additionally, we show that the combined inhibition of Mpro and PLpro is more effective in inhibiting SARS-CoV-2 and the delta variant.
PubMed: 35217718
DOI: 10.1038/s42003-022-03090-9
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.69 Å)
Structure validation

227933

건을2024-11-27부터공개중

PDB statisticsPDBj update infoContact PDBjnumon